Role of the promyelocytic leukaemia protein in cell death regulation.

Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, 72 Huntley Street, London WC1E 6BT, UK.
Cell Death & Disease (Impact Factor: 5.18). 01/2012; 3:e247. DOI: 10.1038/cddis.2011.122
Source: PubMed

ABSTRACT The promyelocytic leukaemia gene PML was originally identified at the t(15;17) translocation of acute promyelocytic leukaemia, which generates the oncogene PML-retinoic acid receptor α. PML epitomises a subnuclear structure called PML nuclear body. Current models propose that PML through its scaffold properties is able to control cell growth and survival at many different levels. Here we discuss the current literature and propose new avenues for investigation.


Available from: David Michod, Jun 02, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNA dysregulation is a common event in leukemia. Polymorphisms in microRNA-binding sites (miRSNPs) in target genes may alter the strength of microRNA interaction with target transcripts thereby affecting protein levels. In this study we aimed at identifying miRSNPs associated with leukemia risk and assessing impact of these miRSNPs on miRNA binding to target transcripts.
    Journal of Hematology & Oncology 06/2014; 7(1):43. DOI:10.1186/1756-8722-7-43 · 4.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Autophagy and the ubiquitin-proteasome pathway (UPP) are the major protein degradation systems in eukaryotic cells. Whereas the former mediate a bulk nonspecific degradation, the UPP allows a rapid degradation of specific proteins. Both systems have been shown to play a role in tumorigenesis, and the interest in developing therapeutic agents inhibiting protein degradation is steadily growing. However, emerging data point to a critical role for autophagy in cellular senescence, an established tumor suppressor mechanism. Recently, a selective protein degradation process mediated by the UPP was also shown to contribute to the senescence phenotype. This process is tightly regulated by E3 ubiquitin ligases, deubiquitinases, and several post-translational modifications of target proteins. Illustrating the complexity of UPP, more than 600 human genes have been shown to encode E3 ubiquitin ligases, a number which exceeds that of the protein kinases. Nevertheless, our knowledge of proteasome-dependent protein degradation as a regulated process in cellular contexts such as cancer and senescence remains very limited. Here we discuss the implications of protein degradation in senescence and attempt to relate this function to the protein degradation pattern observed in cancer cells.
    Cell cycle (Georgetown, Tex.) 05/2014; 13(12). DOI:10.4161/cc.29335 · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significance: Chronic myeloid leukemia (CML) involves the malignant transformation of hematopoietic stem cells, defined largely by the Philadelphia chromosome and expression of the BCR-ABL oncoprotein. Pharmacological tyrosine kinase inhibitors (TKIs) including imatinib mesylate, have overcome limitations in conventional treatment for the improved clinical management of CML. Recent Studies: Accumulated evidence has led to the identification of a subpopulation of quiescent leukemia progenitor cells with stem-like self renewal properties that may initiate leukemogenesis, are also shown to be present in residual disease due to their insensitivity to tyrosine kinase inhibition. Critical issues: The characterisation of quiescent leukemia progenitor cells as a unique cell population in CML pathogenesis has become critical with the complete elucidation of mechanisms involved in their survival independent of BCR-ABL important in the development of novel anticancer strategies. Understanding of these functional pathways in CML progenitor cells will allow for their selective therapeutic targeting. In addition, disease pathogenesis and drug responsiveness is also thought to be modulated by epigenetic regulatory mechanisms such as DNA methylation, histone acetylation and microRNA expression, with a capacity to control CML-associated gene transcription. Future Directions: A number of compounds in combination with tyrosine kinase inhibitors are under preclinical and clinical investigation to assess their synergistic potential in targeting leukemic progenitor cells and/or the epigenome in CML. Despite the collective promise, further research is required in order to refine understanding, and ultimately advance antileukemic therapeutic strategies.
    Antioxidants and Redox Signaling 11/2014; 22(16). DOI:10.1089/ars.2014.6096 · 7.67 Impact Factor